Bank OZK Has $275,000 Stake in Zoetis Inc. (NYSE:ZTS)

Bank OZK trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,690 shares of the company’s stock after selling 219 shares during the period. Bank OZK’s holdings in Zoetis were worth $275,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in Zoetis during the third quarter worth $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter valued at $33,000. Finally, Dunhill Financial LLC increased its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $215.90.

Zoetis Trading Up 1.6 %

ZTS opened at $167.58 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a 50-day simple moving average of $166.30 and a 200 day simple moving average of $177.38. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $75.04 billion, a price-to-earnings ratio of 30.64, a P/E/G ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.19%. Zoetis’s dividend payout ratio is 36.56%.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.